Bachem Holding AG
SIX:BANB
Operating Margin
Bachem Holding AG
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CH |
|
Bachem Holding AG
SIX:BANB
|
3.7B CHF |
22%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD |
15%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
160.1B USD |
18%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
141.3B USD |
22%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
29%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
41.1B CHF |
18%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
30.3B USD |
24%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.6B USD |
15%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
174.6B CNY |
28%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.7B EUR |
14%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
22.1B USD |
29%
|
Bachem Holding AG
Glance View
In the heart of the Swiss pharmaceutical industry, Bachem Holding AG has carved out a distinct niche as a leading player in the peptide manufacturing landscape. Founded by Peter Grogg in 1971, Bachem has grown from a modest laboratory venture into a global powerhouse with an exceptional focus on peptides and oligonucleotide development. These biomolecules, small chains of amino acids, and nucleotides respectively, play crucial roles in modern therapeutics, acting as key components in drug design for treating various ailments. From its headquarters in Bubendorf, Switzerland, Bachem leverages cutting-edge technologies to enhance the purity and scalability of peptide production, meeting the demand from pharmaceutical and biotechnology companies worldwide. By establishing a robust supply chain and maintaining high standards of quality control, the company ensures the reliability and success of its partnerships. At the core of Bachem's business model is the offering of customized products and services tailored to client-specific needs, ranging from research-grade to commercial-scale production. The company generates revenue through long-term contracts and ongoing relationships with key players in the global pharmaceutical industry. As drug discovery advances, Bachem’s role in providing essential active pharmaceutical ingredients (APIs) becomes increasingly central, facilitating the development of novel therapies. The company also invests heavily in research and development to continuously refine its manufacturing processes and expand its service portfolio. By marrying scientific expertise with strategic foresight, Bachem not only anchors itself in the present pharmaceutical landscape but also positions itself for future growth in the biotechnology sector.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Bachem Holding AG's most recent financial statements, the company has Operating Margin of 22%.
You don't have any saved screeners yet